Ozempic and binge eating disorder: what JVN's story leaves out

What did @jvn_official actually say?

Jonathan Van Ness described trying an oral version of semaglutide (what they called "the pill version of Ozempic," likely referring to Rybelsus) and finding it ineffective because binge eating urges were strong enough to override the drug's appetite-suppressing effects. They said they "ate through it" despite GI side effects like nausea and diarrhea. They also mentioned pursuing EMDR therapy as part of eating disorder recovery, and were candid that both health motivations and appearance-related motivations were driving their choices.

This is a personal account, not a medical claim. But several of the underlying mechanisms they're describing are actually grounded in real pharmacology and eating disorder research, which makes it worth examining carefully.

Does the science back this up?

Yes, more than most people realize. GLP-1 receptor agonists reduce appetite primarily through central nervous system pathways and delayed gastric emptying, but binge eating disorder (BED) involves compulsive eating that is partially dissociated from hunger and satiety signals. That distinction matters enormously.

A 2023 review by Brownley et al. in Obesity Reviews noted that GLP-1 agonists may have limited efficacy specifically in patients with active BED because the disorder's behavioral drivers can override pharmacological satiety cues. Oral semaglutide (Rybelsus) also has meaningfully lower bioavailability than injectable semaglutide, roughly 1% absorption under real-world conditions, according to the drug's own prescribing information. That pharmacokinetic gap could further reduce its behavioral impact. So JVN's experience of "eating through it" is not just anecdote. It has a plausible biological basis.

On EMDR: the evidence for EMDR in eating disorder treatment is still limited but emerging. A 2021 pilot study by Bloomgarden and Calogero in Journal of EMDR Practice and Research found promising results for trauma-related eating behaviors, though sample sizes were small.

What did they get wrong (or right)?

They got the core experiential account largely right, and they were more self-aware than most GLP-1 content on TikTok. Acknowledging that appearance-based motivation coexists with health motivation is honest, and that kind of transparency is rare in the "Ozempic journey" genre.

What's worth flagging: JVN uses "Ozempic" interchangeably with oral semaglutide. These are not the same drug in the same form. Ozempic is injectable semaglutide. Rybelsus is the oral tablet. They have different bioavailability profiles, different dosing structures, and different clinical trial data. Conflating them is a common public misconception, and high-follower accounts spreading it makes prescribers' jobs harder.

They did not make any dangerous claims. They did not recommend a dose, suggest a specific treatment protocol, or claim semaglutide cures binge eating disorder. That restraint is worth acknowledging. A lot of GLP-1 content on TikTok does not show the same restraint.

What should you actually know?

If you have binge eating disorder and are considering GLP-1 medications, the clinical picture is genuinely complicated. BED is classified as a psychiatric condition under DSM-5, and GLP-1 drugs are not approved to treat it. Some research suggests semaglutide may reduce binge frequency as a secondary effect, but the data is preliminary.

A 2023 randomized trial by Garvey et al. in Nature Medicine found that semaglutide reduced food cravings and improved control over eating in people with obesity, but the trial did not specifically recruit patients with BED diagnoses. Extrapolating those results to active eating disorders requires caution.

EMDR is a trauma-focused therapy originally developed for PTSD. Using it for eating disorder recovery, as JVN mentions, reflects a growing clinical understanding that many eating disorders are trauma-linked. This is not fringe thinking, but it is not yet standard of care either. Anyone pursuing this combination of approaches should be working with both a prescribing clinician and a mental health provider who specializes in eating disorders, not managing it solo based on podcast recommendations.

The broader point JVN is making, that GLP-1 drugs are not a behavioral override switch, is correct and important. Medication alone does not address the psychological drivers of compulsive eating.

The bottom line

JVN's account is personal, honest, and mostly pharmacologically coherent. The main factual slip is treating oral and injectable semaglutide as interchangeable, which they are not. The more important public health value here is what they modeled: admitting a drug did not work for them, pursuing therapy, and being transparent about mixed motivations. That is a more responsible GLP-1 narrative than most of what this hashtag produces.